Mullhouse Private Equity Trust has led a €2.9m funding round for Revotar Biopharmaceuticals.
Deutsche Life Science, MVC Unternehmensbeteiligungsgesellschaft and Revotar’s early-stage backer Bmp also participated in the financing.
Bmp now owns 44 per cent of the company, having backed it since July 2000.
Revotar is a developer of small molecule anti-inflammatory drugs for the treatment of conditions such as asthma, psoriasis, sepsis, COPD (chronic obstructive lung disease) and other inflammatory indications.
The company is based at Hennigsdorf near Berlin. It plans to use the capital injection for further clinical development of its lead product Bimosiamose, and to advance the rest of its pipeline.